Parotid Lymph Node Metastasis from Eyelid Sebaceous Carcinoma
Conditions
Interventions
None listed
Sponsors
Faculty of Medicine, Niigata University, Niigata, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: PEligible studies include patients with histologically confirmed parotid lymph node metastasis from eyelid sebaceous carcinoma. Patients with isolated parotid lymph node metastasis or combined parotid and cervical lymph node metastases are eligible. Studies must report details of parotid surgery, neck dissection, or postoperative radiotherapy (PORT) and provide data on regional recurrence, lymph node distribution, or oncologic outcomes. For mixed cohorts, only studies in which patients with parotid lymph node metastasis can be identified separately will be included. No restrictions will be applied regarding publication year or language.
Exclusion criteria
Exclusion criteria: The following will be excluded: (1) patients with cervical lymph node metastasis without parotid lymph node metastasis; (2) prophylactic parotidectomy cases without pathological parotid lymph node metastasis; (3) direct invasion of the parotid gland without lymph node metastasis; (4) studies in which patients with parotid lymph node metastasis cannot be identified separately; (5) single case reports, reviews, conference abstracts, editorials, letters, or other publications without original patient data; and (6) studies evaluating only sentinel lymph node biopsy, systemic therapy alone, or primary tumor treatment alone. When duplicate cohorts are identified, only the most informative report will be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Regional recurrence after treatment for parotid lymph node metastasis (parotid and/or cervical regional recurrence). The site of recurrence (parotid region, cervical region, in-field or out-of-field recurrence) and the time to regional recurrence will be recorded. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Occult cervical lymph node metastasis; (2) Distribution of metastatic cervical lymph node levels; (3) Disease-free survival (DFS), overall survival (OS), and disease-specific survival (DSS); (4) Disease status at the last follow-up (no evidence of disease, alive with disease, and dead of disease); (5) Treatment-related complications; and (6) Duration of follow-up. | — |
Countries
Japan
Contacts
Public ContactTakeshi Takahashi
Faculty of Medicine, Niigata University Department of Otolaryngology-Head and Neck Surgery
Outcome results
None listed